Vanda Pharmaceuticals (VNDA) stock saw a 9% premarket drop after FDA rejection of its therapy for gastroparesis, citing need ...

Eli Lilly, a prominent player in the,Healthcare sector,, has experienced a significant rise in its stock price, driven by the ...

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

GLP-1 weight loss medications like Ozempic and Wegovy have become blockbuster ... Other pharmaceutical companies are also entering the race to develop oral GLP-1 treatments. Eli Lilly is testing an ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 584.52% and ...

It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...

Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.